Immuno-Oncology | Specialty

Atezolizumab Combos Highly Effective for Advanced Melanoma

November 7th 2016

The addition of the PD-L1 inhibitor atezolizumab to the MEK inhibitor cobimetinib and the BRAF inhibitor vemurafenib induced a high response rate for patients with BRAF-mutant unresectable melanoma.

Potential for Neoadjuvant Immunotherapy in Bladder Cancer Is Wide Open, Expert Says

November 7th 2016

With immunotherapy agents showing significant promise in bladder cancer, the potential for these agents in the neoadjuvant setting is wide open.

Systemic Immunotherapy Use Expanding Rapidly in Bladder Cancer

November 6th 2016

Following a long drought in the development of bladder cancer treatments, the field is now poised to benefit from a series of rapid advances ushered in by highly effective immunotherapies.

Novel Therapies Offer Hope for BCG-Unresponsive Bladder Cancer

November 5th 2016

A window of opportunity exists in which some patients with non–muscle-invasive bladder cancer could benefit from trying novel second-line therapies prior to surgery.

RCC Experts Consider Immunotherapy Integral to Optimizing Adjuvant Care

November 5th 2016

Looking ahead to 2020, most participants on an expert panel projected that immunotherapy will be critical to optimizing outcomes in the adjuvant setting for patients with renal cell carcinoma.

Dr. Plimack on Significance of CheckMate-025 Trial in RCC

November 5th 2016

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses updated findings from the CheckMate-025 trial, which compared the efficacy of nivolumab (Opdivo) with everolimus (Afinitor) in patients with renal cell carcinoma.

Dr. Cost on Pembrolizumab Plus Axitinib in Patients With RCC

November 5th 2016

Nicholas G. Cost, MD, assistant professor, Surgery-Urology, Department of Pediatric Urology/ Urologic Oncology, University of Colorado Denver, discusses a clinical trial exploring pembrolizumab (Keytruda) plus axitinib (Inlyta) in patients with renal cell carcinoma (RCC).

Dr. Jason Luke on Sequencing Targeted and Immunotherapy Agents in BRAF+ Melanoma

November 4th 2016

Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses the role for immunotherapy and targeted agents in patients with BRAF-positive melanoma.

Speed Critical With Anaplastic Thyroid Cancer Diagnosis, Treatment

November 3rd 2016

Enrolling clinical trials can be a long process, especially in rare diseases with limited patient populations. This is a particularly significant issue for patients with anaplastic thyroid cancer, an extremely rare and aggressive disease.

Targeting CD47 May Open "Exciting" Door to Novel Combos

November 3rd 2016

Gregory L. Beatty, MD, PhD, who focuses his research on understanding the role of innate immunity in gastrointestinal malignancies, discusses CD47 as an anticancer target.

Dr. Mohammed Haseebuddin on Expanding Role for Immunotherapy in RCC

November 3rd 2016

Mohammed Haseebuddin, MD, a fellow in Urologic Oncology at Fox Chase Cancer Center, discuses why continued research into immunotherapy in clear cell renal cell carcinoma (RCC) is important, particularly in the adjuvant and neoadjuvant settings.

Dr. David L. Rimm on the Continued Role for PD-L1 Testing in NSCLC

November 3rd 2016

David L. Rimm, MD, PhD, professor of pathology and of medicine, director of pathology tissue services, director of translational pathology, Yale Cancer Center, discusses the continued role for PD-L1 testing to predict response with checkpoint inhibitors in non­–small cell lung cancer (NSCLC).

Jena D. French on Anti-PD-1/Lenvatinib Combo in Differentiated Thyroid Cancer

November 3rd 2016

Jena D. French, PhD, instructor of medicine, division of endocrinology, metabolism and diabetes, Anschutz Medical Campus, University of Colorado, discusses the potential for immunotherapy combinations with lenvatinib in differentiated thyroid cancer.

Dr. Pal on Sequencing Challenges for the Treatment of Patients With RCC

November 3rd 2016

Sumanta Kumar Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the challenges with sequencing the therapies available for patients with renal cell carcinoma (RCC). Pal shared this insight in an interview during the 2016 OncLive State of the Science Summit on GU Cancer.

Dr. Schoenfeld on Preventing Immune Suppression With Radiation and Immunotherapy Combos

November 2nd 2016

Jonathan D. Schoenfeld, MD, MPhil, MPH, director, melanoma radiation oncology, physician, assistant professor of radiation oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses challenges with immune suppression with radiation and immunotherapy combinations.

Expert Discusses Promise of Nivolumab in Advanced Bladder Cancer

November 1st 2016

Results from the phase II CheckMate-275 trial demonstrated favorable safety and efficacy with the PD-1 inhibitor nivolumab as a second-line treatment for patients with metastatic urothelial cancer who have progressed on first-line chemotherapy.

Using All Modalities Key to Expanding Immunotherapy Success in Oncology

November 1st 2016

While immunotherapy is currently only beneficial in select cancers, it is possible for this type of treatment to eventually work for all patients.

The Future of Non-Driver Lung Adenocarcinoma

October 31st 2016

Cost Considerations in Non-Driver NSCLC Management

October 31st 2016

Nintedanib in Lung Adenocarcinoma: Managing Toxicities

October 31st 2016